Literature DB >> 93544

Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins.

O Thulesius, J E Gjöres, E Berlin.   

Abstract

ST 1059, the pharmacologically active metabolite of midodrine, is a powerful vasoconstrictor compound, acting by stimulation of alpha-receptors. It elicited 80% of noradrenaline-induced contraction of human veins.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 93544     DOI： 10.1007/bf00568204

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  5 in total

1.  [The pharmacological properties of Midodrin and its clinical application in patients with hypotensive circulatory disturbance (author's transl)].

Authors:  O Lachner; C Lillie; A Rot
Journal:  Wien Klin Wochenschr       Date:  1974-06-14       Impact factor: 1.704

Review 2.  Pathophysiological classification and diagnosis of orthostatic hypotension.

Authors:  O Thulesius
Journal:  Cardiology       Date:  1976       Impact factor: 1.869

3.  [Treatment of hypotensive circular dysregulation using Gutron in practice].

Authors:  H Kratz
Journal:  Wien Med Wochenschr       Date:  1975-03-21

4.  Physiological and pharmacological studies on isolated human bronchial preparations.

Authors:  O Thulesius; J Boe; E Berlin
Journal:  Scand J Respir Dis       Date:  1978-04

5.  Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059.

Authors:  H Pittner; H Stormann; R Enzenhofer
Journal:  Arzneimittelforschung       Date:  1976
  5 in total
  9 in total

1.  Effect of Alpha-1-Adrenergic Agonist, Midodrine for the Management of Long-Standing Neurogenic Shock in Patient with Cervical Spinal Cord Injury: A Case Report.

Authors:  Taikwan Kim; Cheol Su Jwa
Journal:  Korean J Neurotrauma       Date:  2015-10-31

Review 2.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

Review 3.  Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.

Authors:  K J McClellan; L R Wiseman; M I Wilde
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

4.  Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine.

Authors:  Luis E Okamoto; André Diedrich; Franz J Baudenbacher; René Harder; Jonathan S Whitfield; Fahad Iqbal; Alfredo Gamboa; Cyndya A Shibao; Bonnie K Black; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2016-06-06       Impact factor: 10.190

5.  Pharmacological actions of the main metabolites of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Idiopathic orthostatic hypotension, midodrine, and anaesthesia.

Authors:  P J Osborne; L W Lee
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

7.  Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

8.  Pharmacological analysis of positive chronotropic and inotropic responses to etilefrine in isolated dog heart preparations.

Authors:  Y Karasawa; Y Furukawa; M Murakami; L M Ren; S Takayama; S Chiba
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

Review 9.  Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.

Authors:  D McTavish; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.